Travere Therapeutics (TVTX) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Travere Therapeutics Revenue Highlights


Latest Revenue (Y)

$145.24M

Latest Revenue (Q)

$62.90M

Main Segment (Y)

License

Travere Therapeutics Revenue by Period


Travere Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$145.24M-31.50%
2022-12-31$212.02M-6.80%
2021-12-31$227.49M14.71%
2020-12-31$198.32M13.11%
2019-12-31$175.34M6.75%
2018-12-31$164.25M6.01%
2017-12-31$154.94M15.98%
2016-12-31$133.59M33.74%
2015-12-31$99.89M254.19%
2014-12-31$28.20M100.00%
2013-12-31-100.00%
2012-12-31-100.00%
2012-02-29-100.00%
2011-02-28-100.00%
2010-02-28-100.00%
2009-02-28--

Travere Therapeutics generated $145.24M in revenue during NA 2023, up -31.50% compared to the previous quarter, and up 88.43% compared to the same period a year ago.

Travere Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$62.90M16.23%
2024-06-30$54.12M30.80%
2024-03-31$41.37M-8.18%
2023-12-31$45.06M21.47%
2023-09-30$37.09M-37.86%
2023-06-30$59.70M4.74%
2023-03-31$56.99M2.01%
2022-12-31$55.87M4.43%
2022-09-30$53.50M-1.24%
2022-06-30$54.17M11.71%
2022-03-31$48.49M-15.31%
2021-12-31$57.25M-16.08%
2021-09-30$68.22M24.90%
2021-06-30$54.62M15.21%
2021-03-31$47.41M-7.01%
2020-12-31$50.98M-0.31%
2020-09-30$51.14M5.59%
2020-06-30$48.43M1.38%
2020-03-31$47.77M2.32%
2019-12-31$46.69M5.21%
2019-09-30$44.37M-0.75%
2019-06-30$44.71M12.98%
2019-03-31$39.57M-9.60%
2018-12-31$43.77M7.53%
2018-09-30$40.71M-1.53%
2018-06-30$41.34M7.56%
2018-03-31$38.43M-8.88%
2017-12-31$42.18M4.55%
2017-09-30$40.34M3.97%
2017-06-30$38.80M15.41%
2017-03-31$33.62M-9.93%
2016-12-31$37.33M9.96%
2016-09-30$33.95M1.90%
2016-06-30$33.31M14.83%
2016-03-31$29.01M-4.73%
2015-12-31$30.45M8.72%
2015-09-30$28.00M16.36%
2015-06-30$24.07M38.55%
2015-03-31$17.37M23.34%
2014-12-31$14.08M68.71%
2014-09-30$8.35M45.40%
2014-06-30$5.74M20479.69%
2014-03-31$27.90K100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-11-30-100.00%
2012-08-31-100.00%
2012-05-31-100.00%
2012-02-29-100.00%
2011-11-30-100.00%
2011-08-31-100.00%
2011-05-31-100.00%
2011-02-28-100.00%
2010-11-30-100.00%
2010-08-31-100.00%
2010-05-31--

Travere Therapeutics generated $62.90M in revenue during Q3 2024, up 16.23% compared to the previous quarter, and up 105.36% compared to the same period a year ago.

Travere Therapeutics Revenue Breakdown


Travere Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
License$17.70M----
Active Pharmaceutical Ingredient$3.30M----
Bile Acid Products-$102.56M$95.65M$89.44M$79.70M
Tiopronin Products-$97.97M$115.12M$108.88M-
Product-$200.53M$210.78M--
Thiola License----$95.64M

Travere Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License (84.29%), and Active Pharmaceutical Ingredient (15.71%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
Product$61.00M$52.18M$39.98M$57.01M$50.28M$52.34M$50.79M$50.95M$46.44M$54.58M$54.17M---------
License$1.90M$1.94M$1.39M$14.54M$3.16M$2.67M--------------
Active Pharmaceutical Ingredient----$3.30M---------------
Bile Acid Products-----$27.50M$26.11M$26.53M$25.42M$25.53M$25.07M$24.35M$24.97M$21.96M$22.67M$22.91M$21.57M$22.28M$20.44M-
Tiopronin Products-----$26.05M$21.17M$25.82M$25.37M$25.42M$21.37M$29.82M$29.64M$25.44M$28.31M$28.23M$26.86M$25.49M--

Travere Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (96.98%), and License (3.02%).

Travere Therapeutics Revenue Breakdown by Country

Quarterly Revenue by Country

CountryMar 22
FRANCE$8.00M

Travere Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 22: FRANCE (100.00%).

Travere Therapeutics Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
APLSApellis Pharmaceuticals$366.28M$179.14M
LEGNLegend Biotech$285.14M$93.99M
TVTXTravere Therapeutics$145.24M$62.90M
PTGXProtagonist Therapeutics$60.00M$4.17M
IDYAIDEAYA Biosciences$23.39M-
ANABAnaptysBio$17.16M$10.97M
MGTXMeiraGTx$14.02M$282.00K
RVMDRevolution Medicines, Inc. Warrant$11.58M-
RNAAvidity Biosciences$9.56M$2.04M
STOKStoke Therapeutics$8.78M$4.22M
CYTKCytokinetics$7.53M$249.00K
FIXXQ32 Bio$1.16M-
KROSKeros Therapeutics$151.00K$83.00K
GPCRStructure Therapeutics--
PCVXVaxcyte--
NUVLNuvalent--
COGTCogent Biosciences--
DICEDICE Therapeutics--
CERECerevel Therapeutics--
VTYXVentyx Biosciences--
AKROAkero Therapeutics--

TVTX Revenue FAQ


Travere Therapeutics's yearly revenue for 2023 was $145.24M, representing a decrease of -31.50% compared to 2022. The company's yearly revenue for 2022 was $212.02M, representing a decrease of -6.80% compared to 2021. TVTX's yearly revenue for 2021 was $227.49M, representing an increase of 14.71% compared to 2020.

Travere Therapeutics's quarterly revenue for Q3 2024 was $62.9M, a 16.23% increase from the previous quarter (Q2 2024), and a 69.56% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $54.12M, a 30.80% increase from the previous quarter (Q1 2024), and a -9.35% decrease year-over-year (Q2 2023). TVTX's quarterly revenue for Q1 2024 was $41.37M, a -8.18% decrease from the previous quarter (Q4 2023), and a -27.41% decrease year-over-year (Q1 2023).

Travere Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -36.16%, and for the last 5 years (2019-2023) was -17.17%.

Travere Therapeutics's revenue streams in c 23 are License, and Active Pharmaceutical Ingredient. License generated $17.7M in revenue, accounting 84.29% of the company's total revenue Active Pharmaceutical Ingredient generated $3.3M in revenue, accounting 15.71% of the company's total revenue

For the fiscal year ending Dec 23, the largest source of revenue of Travere Therapeutics was License. This segment made a revenue of $17.7M, representing 84.29% of the company's total revenue.